FIELD: medicine. SUBSTANCE: thrombolytically active proteins are combined with anticoagulants when anticoagulant is not heparin. Anticoagulant is administrated as an intravenous injection of impact acute dose while thrombolytically active protein can be administrated by an intravenous impact acute dose or by an intravenous infusion. Invention ensures to avoid repeated occlusion that results to decrease of the course of acute myocardial infarction and decrease of lethality by 30%. EFFECT: enhanced curative effectiveness of combination. 10 cl, 3 tbl, 5 dwg,1 ex
Authors
Dates
2001-05-10—Published
1995-03-22—Filed